The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsi
- PDF / 850,874 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 73 Downloads / 164 Views
RESEARCH ARTICLE
Open Access
The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessivecompulsive disorder: a randomized, double-blind, sham-controlled, clinical trial Sadegh Yoosefee1,2, Man Amanat3, Mona Salehi3, Seyed Vahid Mousavi4, Jamshid Behzadmanesh5, Victoria Safary5, Ali Yoonesi6 and Bahman Salehi5*
Abstract Background: Obsessive-compulsive disorder (OCD) is an anxiety disorder that causes impairment in daily activities. This study aimed to assess the safety and efficacy of transcranial direct current stimulation (tDCS) as adjunctive therapy with fluoxetine in individuals diagnosed with moderate to severe OCD. Methods: This is a randomized, double-blind sham-controlled trial. Individuals with OCD who had baseline YaleBrown obsessive-compulsive scale (Y-BOCS) of > 15 were enrolled. Eligible cases were randomly assigned in 1:1 ratio to receive either 20-min-period of stimulation with tDCS and fluoxetine (experimental arm) or fluoxetine only (sham control arm). The anodal electrode of tDCS was placed over the left dorsolateral prefrontal cortex (Fp3) and the cathodal electrode was placed over the right orbitofrontal cortex (F8). Two mA electrical stimulation with the tDCS was used for 20 min in individuals of experimental group. In the control group, electrodes were placed and stimulation was administered for 30 s to induce the same skin sensation as in experimental group. This procedure was performed three times per week for 8 weeks. Y-BOCS test was assessed at baseline, week 4 (after 12th stimulation), week 8 (after 24th stimulation), and 1 month after the last stimulation. The primary endpoints were the mean changes in Y-BOCS total score from baseline to the last visit. The secondary endpoints were the mean changes in obsession and compulsion sub-scores from baseline to the last visit. Adverse events were also assessed. Mixed design repeated measures analysis of variance assessed the endpoints. Results: Sixty individuals (30 in each group) were participated. All individuals in control group and 28 cases in experimental arm completed the trial. The mean Y-BOCS (F(1.85) = 30.83; P < 0.001), OCD obsession (F(2.23) = 25.01; P < 0.001), and compulsion (F(2.06) = 10.81; P < 0.001) scores decreased significantly during the study. No statistical differences were, however, detected between experimental and control groups (P > 0.05). The tDCS was well tolerated and no major adverse events were reported. (Continued on next page)
* Correspondence: [email protected] 5 Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indica
Data Loading...
